Survodutide: difference between revisions
Diff·revision 6 → 7·22:05, 18 Jan 2025
Difference between revision 6 and revision 7 of Survodutide. 5 lines changed; the page grew by 648 bytes.
| Revision 6 — 12:31, 29 Dec 2024 NeutralNikolai (talk) move the trade-name history out of the lead and into §Regulatory history 3,325 bytes ±0 | Revision 7 — 22:05, 18 Jan 2025 Chromatokid (talk) the half-life in the lead was the terminal figure; label it as such 3,973 bytes +648 | ||
|---|---|---|---|
| 20 | Reported ''in vitro'' ratios place survodutide closer to balanced than the triple agonist [[Retatrutide|retatrutide]], though as always such ratios are assay-dependent and are not comparable across publications.{{r|blueher2024}} | 20 | Reported ''in vitro'' ratios place survodutide closer to balanced than the triple agonist [[Retatrutide|retatrutide]], though as always such ratios are assay-dependent and are not comparable across publications.{{r|blueher2024}} |
| 21 | 21 | ||
| + | 22 | == Reported clinical findings == | |
| + | 23 | A 46-week phase 2 trial in adults with obesity and without diabetes reported dose-dependent weight reduction reaching approximately 19% at the highest dose, against approximately 2% for placebo. Escalation was over 20 weeks, longer than in comparable programmes, reflecting tolerability constraints.{{r|blueher2024}} | |
| + | 24 | ||
| + | 25 | A separate phase 2 trial in biopsy-confirmed metabolic dysfunction-associated steatohepatitis reported improvement in histological endpoints at 48 weeks. Histological endpoints in that condition are notoriously variable between readers, and the trial's own reporting acknowledges the limitation. | |
| + | 26 | ||
| 22 | == References == | 27 | == References == |
| 23 | {{reflist}} | 28 | {{reflist}} |